Get the Stockscreener App
3.50
4.79%
0.16
After Hours:
3.50
Recursion Pharmaceuticals Inc stock is traded at $3.50, with a volume of 22.83M.
It is up +4.79% in the last 24 hours and up +13.64% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.34
Open:
$3.39
24h Volume:
22.83M
Relative Volume:
1.11
Market Cap:
$1.88B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-2.9113
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
+10.76%
1M Performance:
+13.64%
6M Performance:
+2.34%
1Y Performance:
-26.78%
1-Day Range:
$3.37
$3.6299
1-Week Range:
$2.92
$3.6299
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.50 | 1.79B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
Recursion Pharmaceuticals Stock Climbs 13% As AI Drug Pipeline Progress And Spending Cuts Boost Sentiment - TIKR.com
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
RXRX Stock Steadies As AI Drug Platform Gains Traction And Cash Burn Tightens - StocksToTrade
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Pipeline and AI Platform Developments - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes - Stock Titan
Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Recursion Pharmaceuticals (RXRX) Slips 1.58% as Stock Holds Above Key $2.95 SupportTriple EMA - vinanet.vn
Recursion Pharmaceuticals (RXRX) Dips 1.42% to $3.12 as Key Support Holds at $2.96Wave Truncation - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - Yahoo Finance
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 - Moomoo
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts - Moomoo
Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX - marketbeat.com
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech) - 24/7 Wall St.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside of Over 120% Sparks Investor Interest - DirectorsTalk Interviews
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. - Pluang
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Sahm
What Does The Future Hold For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)? These Analysts Have Been Cutting Their Estimates - Moomoo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19% - simplywall.st
Recursion Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-08-09 - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen - marketbeat.com
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - simplywall.st
Recursion Pharmaceuticals director Blake Borgeson sells $97,500 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Recursion Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Recursion Pharmaceuticals Inc (RXRX) Stock Analysis & Forecast - TradingKey
Recursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 3 - GuruFocus
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals Insiders Sell US$790k Of Stock, Possibly Signalling Caution - Moomoo
Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Sinks As Cash Burn Dominates AI Drug Story - Sahm
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value - simplywall.st
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):